MIRNA-371а-3r expression as a predictive factor in patients with germ cell testicular tumors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
GCTT is more often diagnosed in the age group of 20–35 years, thanks to the success of chemotherapy in most patients it is possible to achieve long-term remission or recovery. The search for new markers is relevant, since an increase of the level of standard markers (AFP, XGT and LDH) is observed in 60% of the cases.
The objective: to study the possibility of using miRNA-367-3p as a prognostic marker in patients with GCTT.
Materials and methods. The expression of miRNA-367-3p in the blood serum was studied in 24 patients with GCTT in different stages, control – 2 patients with rhabdomyosarcoma and acute epididymitis.
Results. Depending on the stage of disease and the morphological structure of the primary tumor, active observation or chemotheraphy was performed. miRNA-367-3p was determined by reverse transcription in real-time PCR.
Conclusion. The sensitivity/specificity of miRNA-367-3p exceeds those for AFP and HGT, so, miRNA-367-3p can be considered as a molecular marker for GCTT; in teratomatous tumors the level of miRNA-367-3p is minimal or no expression; in nonseminomatous tumors, the level of miRNA-367-3p is statistically higher than in seminomas. Preliminary data indicate a correlation of the level of miRNA-367-3p with complete or incomplete remission after chemotherapy, but the hypothesis requires confirmation on a larger number of patients.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Catto J. MicroRNA in prostate, bladder, and kidney cancer: a systematic review / J. Catto, A. Alcaraz, A. Bjartell [et al.] // Eur Urol. – 2011. – V. 59 (5). – P. 671–81.
Spiekermann M. MicroRNA miR371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker / M. Spiekermann, G. Belge, N. Winter [et al.] // Andrology. – 2015. – V. 3 (1). – P. 78–84.
Rounge T. Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs / T. Rounge, K. Furu, R. Skotheim [et al.] // Mol Cancer. – 2015. – V. 12 (14). – P. 150–153.
Syring I. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer / I. Syring, J. Bartels, S. Holdenrieder [et al.] // J Urol. – 2015. – V. 193 (1). – P. 331–7.
Gillis A. Target serum miRNA (TSmiR) test for diagnosis and follow-up of testicular germ cell cancer patients: a proof of principle / A. Gillis, M. Rijlaarsdam, R. Eini [et al.] // Mol Oncol. – 2013. – V. 7 (6). – P. 1083–92.
Radtke A. Can germ cell neolasia in situ be diagnosed by measuring serum levels of microRNA371a-3p? / A. Radtke, J.F. Cremers, S. Kliesch [et al.] // J Cancer Res Clin Oncol. – 2017. – V. 143 (11). – P. 2383– 2392.
Dieckman K. Serum Levels of Micro RNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. / K. Dieckman, A. Radtke, Spiekermann M [et al.] // Eur Urol. – 2017. – V. 71 (2). – P. 213–220.
